免疫抑制
胶质瘤
医学
FOXP3型
白细胞介素2受体
免疫系统
免疫学
癌症研究
单克隆抗体
抗体
T细胞
作者
Eleanor A Vega,Michael W. Graner,John H. Sampson
出处
期刊:Future Oncology
[Future Medicine]
日期:2008-06-01
卷期号:4 (3): 433-442
被引量:58
标识
DOI:10.2217/14796694.4.3.433
摘要
Despite maximal therapy, malignant gliomas have a very poor prognosis. Patients with glioma express significant immune defects, including CD4 lymphopenia, increased fractions of regulatory T cells in peripheral blood and shifts in cytokine profiles from Th1 to Th2. Recent studies have focused on ways to combat immunosuppression in patients with glioma as well as in animal models for glioma. We concentrate on two specific ways to combat immunosuppression: inhibition of TGF-β signaling and modulation of regulatory T cells. TGF-β signaling can be interrupted by antisense oligonucleotide technology, TGF-β receptor I kinase inhibitors, soluble TGF-β receptors and antibodies against TGF-β. Regulatory T cells have been targeted with antibodies against T-cell markers, such as CD25, CTLA-4 and GITR. In addition, vaccination against Foxp3 has been explored. The results of these studies have been encouraging; combating immunosuppression may be one key to improving prognosis in malignant glioma.
科研通智能强力驱动
Strongly Powered by AbleSci AI